These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24217280)

  • 1. Increased cerebrospinal fluid tau levels in logopenic variant of Alzheimer's disease.
    Magnin E; Paquet C; Formaglio M; Croisile B; Chamard L; Miguet-Alfonsi C; Tio G; Dumurgier J; Roullet-Solignac I; Sauvée M; Thomas-Antérion C; Vighetto A; Hugon J; Vandel P
    J Alzheimers Dis; 2014; 39(3):611-6. PubMed ID: 24217280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid biomarkers can play a pivotal role in the diagnostic work up of primary progressive aphasia.
    Santangelo R; Coppi E; Ferrari L; Bernasconi MP; Pinto P; Passerini G; Comi G; Magnani G
    J Alzheimers Dis; 2015; 43(4):1429-40. PubMed ID: 25201781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is descriptive writing useful in the differential diagnosis of logopenic variant of primary progressive aphasia, Alzheimer's disease and mild cognitive impairment?
    Sitek EJ; Barczak A; Kluj-Kozłowska K; Kozłowski M; Barcikowska M; Sławek J
    Neurol Neurochir Pol; 2015; 49(4):239-44. PubMed ID: 26188940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease.
    Louwersheimer E; Keulen MA; Steenwijk MD; Wattjes MP; Jiskoot LC; Vrenken H; Teunissen CE; van Berckel BN; van der Flier WM; Scheltens P; van Swieten JC; Pijnenburg YA
    J Alzheimers Dis; 2016; 51(2):581-90. PubMed ID: 26890751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phonological short-term memory in logopenic variant primary progressive aphasia and mild Alzheimer's disease.
    Meyer AM; Snider SF; Campbell RE; Friedman RB
    Cortex; 2015 Oct; 71():183-9. PubMed ID: 26232551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly Elevated Cerebrospinal Fluid Total Tau Level Reflects Higher Likelihood of Non-Amnestic Subtype of Alzheimer's Disease.
    Pillai JA; Bonner-Jackson A; Bekris LM; Safar J; Bena J; Leverenz JB
    J Alzheimers Dis; 2019; 70(4):1051-1058. PubMed ID: 31306137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions between amyloid-β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease.
    Kristofikova Z; Ricny J; Kolarova M; Vyhnalek M; Hort J; Laczo J; Sirova J; Ripova D
    J Alzheimers Dis; 2014; 42 Suppl 3():S91-8. PubMed ID: 24670397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease.
    Le Bastard N; Aerts L; Sleegers K; Martin JJ; Van Broeckhoven C; De Deyn PP; Engelborghs S
    J Alzheimers Dis; 2013; 33(3):807-22. PubMed ID: 23034521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropsychological Similarities and Differences Between Amnestic Alzheimer's Disease and its Non-Amnestic Variants.
    Mendez MF; Monserratt LH; Liang LJ; Chavez D; Jimenez EE; Maurer JJ; Laffey M
    J Alzheimers Dis; 2019; 69(3):849-855. PubMed ID: 31156165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF levels of Aβ1-38/Aβ1-40/Aβ1-42 and (11)C PiB-PET studies in three clinical variants of primary progressive aphasia and Alzheimer's disease.
    Ikeda M; Tashiro Y; Takai E; Kurose S; Fugami N; Tsuda K; Arisaka Y; Kodaira S; Fujita Y; Makioka K; Mizuno Y; Shimada H; Harigaya Y; Takatama M; Amari M; Yamazaki T; Yamaguchi H; Higuchi T; Okamoto K; Tsushima Y; Ikeda Y
    Amyloid; 2014 Dec; 21(4):238-45. PubMed ID: 25139672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
    Alexopoulos P; Guo LH; Jiang M; Bujo H; Grimmer T; Förster S; Drzezga A; Kurz A; Perneczky R
    J Alzheimers Dis; 2013; 36(2):401-8. PubMed ID: 23609762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
    Visser PJ; Verhey F; Knol DL; Scheltens P; Wahlund LO; Freund-Levi Y; Tsolaki M; Minthon L; Wallin AK; Hampel H; Bürger K; Pirttila T; Soininen H; Rikkert MO; Verbeek MM; Spiru L; Blennow K
    Lancet Neurol; 2009 Jul; 8(7):619-27. PubMed ID: 19523877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting.
    Malnar M; Kosicek M; Bene R; Tarnik IP; Pavelin S; Babic I; Brajenovic-Milic B; Hecimovic H; Titlic M; Trkanjec Z; Demarin I; Hecimovic S
    Acta Neurobiol Exp (Wars); 2012; 72(3):264-71. PubMed ID: 23093013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.
    Vos SJ; van Rossum IA; Verhey F; Knol DL; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Frisoni GB; Froelich L; Nobili F; van der Flier W; Blennow K; Wolz R; Scheltens P; Visser PJ
    Neurology; 2013 Mar; 80(12):1124-32. PubMed ID: 23446677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Correlates of Alzheimer's Disease Cerebrospinal Fluid Analytes in Primary Progressive Aphasia.
    Norise C; Ungrady M; Halpin A; Jester C; McMillan CT; Irwin DJ; Cousins KA; Grossman M
    Front Neurol; 2019; 10():485. PubMed ID: 31133977
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
    Mroczko B; Groblewska M; Zboch M; Muszyński P; Zajkowska A; Borawska R; Szmitkowski M; Kornhuber J; Lewczuk P
    J Alzheimers Dis; 2015; 43(3):1031-7. PubMed ID: 25159667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neural Correlates of Verbal Episodic Memory and Lexical Retrieval in Logopenic Variant Primary Progressive Aphasia.
    Win KT; Pluta J; Yushkevich P; Irwin DJ; McMillan CT; Rascovsky K; Wolk D; Grossman M
    Front Neurosci; 2017; 11():330. PubMed ID: 28659753
    [No Abstract]   [Full Text] [Related]  

  • 19. Primary Progressive Aphasia in the Network of French Alzheimer Plan Memory Centers.
    Magnin E; Démonet JF; Wallon D; Dumurgier J; Troussière AC; Jager A; Duron E; Gabelle A; de la Sayette V; Volpe-Gillot L; Tio G; Evain S; Boutoleau-Bretonnière C; Enderle A; Mouton-Liger F; Robert P; Hannequin D; Pasquier F; Hugon J; Paquet C;
    J Alzheimers Dis; 2016 Oct; 54(4):1459-1471. PubMed ID: 27589533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease.
    Johansson P; Åberg D; Johansson JO; Mattsson N; Hansson O; Ahrén B; Isgaard J; Åberg ND; Blennow K; Zetterberg H; Wallin A; Svensson J
    Psychoneuroendocrinology; 2013 Sep; 38(9):1729-37. PubMed ID: 23473966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.